We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CAH's Q1 EPS rose 35.6% to $2.55, topping estimates, with revenues up 22% to $64B.
CAH's Pharmaceutical profit grew 26%, while Medical segment profit jumped from $8M to $46M.
CAH raised 2026 EPS view to $9.65-$9.85, reflecting solid momentum and diversified growth.
Cardinal Health, Inc. (CAH - Free Report) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.55, which beat the Zacks Consensus Estimate of $2.21 by 15.4%. The bottom line also improved 35.6% year over year.
GAAP EPS in the quarter was $1.88 compared with $1.70 in the year-ago period.
Revenue Details
Sales were up 22% on a year-over-year basis to $64 billion. The top line beat the Zacks Consensus Estimate by 8.4%.
Cardinal Health, Inc. Price, Consensus and EPS Surprise
Pharmaceutical revenues were up 23% to $59.2 billion on a year-over-year basis. This growth was driven by branded and specialty pharmaceutical sales growth from existing and new Pharmaceutical Distribution and Specialty Solutions customers.
Pharmaceutical profit totaled $667 million, up 26% from the year-ago period’s level. The upside was driven by growth in brand and specialty products and MSO platforms (including GI Alliance), and contributions from positive generics program performance.
Global Medical Products and Distribution
Revenues in this segment totaled $3.2 billion, up 2% year over year, driven by growth volume from existing customers.
The segment reported a profit of $46 million compared with $8 million in the year-ago quarter.
Other
This segment includes three operating segments — at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics. Sales totaled $1.6 billion, up 38% year over year.
The segment’s profit amounted to $166 million, up 60% from the year-ago level. The upside was driven by robust performance across the three operating segments.
Margin Analysis
Gross profit increased 22% year over year to $2.32 billion.
As a percentage of revenues, the gross margin in the reported quarter was 3.6%, almost flat year over year.
Distribution, selling, general and administrative expenses totaled $1.46 billion, up 14% year over year.
Operating income amounted to $668 million, up 18% year over year. Adjusted operating income increased 37.1% year over year to $857 million.
Financial Update
The company exited the reported quarter with cash and cash equivalents of $4.59 billion compared with $3.87 billion in the fiscal fourth quarter of 2025.
Net cash provided by operating activities totaled $973 million against $1.65 billion in net cash used in the year-ago period.
2026 View Raised
Cardinal Health raised its fiscal 2026 earnings guidance. The company anticipates adjusted EPS to be between $9.65 and $9.85, up from the previously issued preliminary outlook of $9.30-$9.50. The Zacks Consensus Estimate for the same is pegged at $9.45.
The company expects revenues from its Pharmaceutical segment to grow 11-13% year over year. Segmental profit is also likely to increase 16-19%.
Revenues from the Medical segment are estimated to grow 2-4%. Segmental profit is expected to be at least $140 million.
Revenues from the Other segment are likely to grow 26-28%. Segmental profit is expected to increase 29-31%.
Conclusion
Cardinal Health reported robust first-quarter fiscal 2026 results, with earnings and sales beating estimates. Quarterly results were marked by broad-based profit growth across all operating segments. Pharmaceutical and Specialty Solutions benefited from robust brand and specialty drug sales, excluding the impact of a major contract expiration, while Global Medical Products and Distribution posted double-digit profit gains on higher volumes. The Other segment also saw significant expansion, supported by acquisitions and growth in at-Home Solutions, Nuclear and Precision Health Solutions, and logistics services.
Following positive results, shares of CAH were up 10% in pre-market trading. The company’s shares have gained 39.1% so far this year compared with the industry’s 4.1% increase. The S&P 500 Index has gained 18.6% in the period.
Image Source: Zacks Investment Research
Management’s ability to drive profitability while investing in strategic initiatives underscores the resilience and diversification of Cardinal Health’s business model. Ongoing progress in technology integration, supply-chain optimization, and specialty platform expansion further strengthen the company’s competitive positioning. With solid momentum across all five segments and a raised full-year outlook, Cardinal Health enters the remainder of fiscal 2026 with confidence.
CAH’s Zacks Rank and Stocks to Consider
Cardinal Health carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Solventum Corporation (SOLV - Free Report) , Boston Scientific Corporation (BSX - Free Report) and HealthEquity (HQY - Free Report) .
Solventum, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 4.1%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.91%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Solventum’s shares have gained 8.2% compared with the industry’s 6.2% growth so far this year.
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.1%.
Boston Scientific’s shares have gained 13.2% compared with the industry’s 5.6% growth so far this year.
HealthEquity, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.7%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 11.05%.
HealthEquity’s shares have risen 0.6% compared with the industry’s 6.2% growth so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CAH Q1 Earnings Beat Estimates, '26 EPS View Up, Stock Gains
Key Takeaways
Cardinal Health, Inc. (CAH - Free Report) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.55, which beat the Zacks Consensus Estimate of $2.21 by 15.4%. The bottom line also improved 35.6% year over year.
GAAP EPS in the quarter was $1.88 compared with $1.70 in the year-ago period.
Revenue Details
Sales were up 22% on a year-over-year basis to $64 billion. The top line beat the Zacks Consensus Estimate by 8.4%.
Cardinal Health, Inc. Price, Consensus and EPS Surprise
Cardinal Health, Inc. price-consensus-eps-surprise-chart | Cardinal Health, Inc. Quote
Segmental Analysis
Pharmaceutical and Specialty Solutions
Pharmaceutical revenues were up 23% to $59.2 billion on a year-over-year basis. This growth was driven by branded and specialty pharmaceutical sales growth from existing and new Pharmaceutical Distribution and Specialty Solutions customers.
Pharmaceutical profit totaled $667 million, up 26% from the year-ago period’s level. The upside was driven by growth in brand and specialty products and MSO platforms (including GI Alliance), and contributions from positive generics program performance.
Global Medical Products and Distribution
Revenues in this segment totaled $3.2 billion, up 2% year over year, driven by growth volume from existing customers.
The segment reported a profit of $46 million compared with $8 million in the year-ago quarter.
Other
This segment includes three operating segments — at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics. Sales totaled $1.6 billion, up 38% year over year.
The segment’s profit amounted to $166 million, up 60% from the year-ago level. The upside was driven by robust performance across the three operating segments.
Margin Analysis
Gross profit increased 22% year over year to $2.32 billion.
As a percentage of revenues, the gross margin in the reported quarter was 3.6%, almost flat year over year.
Distribution, selling, general and administrative expenses totaled $1.46 billion, up 14% year over year.
Operating income amounted to $668 million, up 18% year over year. Adjusted operating income increased 37.1% year over year to $857 million.
Financial Update
The company exited the reported quarter with cash and cash equivalents of $4.59 billion compared with $3.87 billion in the fiscal fourth quarter of 2025.
Net cash provided by operating activities totaled $973 million against $1.65 billion in net cash used in the year-ago period.
2026 View Raised
Cardinal Health raised its fiscal 2026 earnings guidance. The company anticipates adjusted EPS to be between $9.65 and $9.85, up from the previously issued preliminary outlook of $9.30-$9.50. The Zacks Consensus Estimate for the same is pegged at $9.45.
The company expects revenues from its Pharmaceutical segment to grow 11-13% year over year. Segmental profit is also likely to increase 16-19%.
Revenues from the Medical segment are estimated to grow 2-4%. Segmental profit is expected to be at least $140 million.
Revenues from the Other segment are likely to grow 26-28%. Segmental profit is expected to increase 29-31%.
Conclusion
Cardinal Health reported robust first-quarter fiscal 2026 results, with earnings and sales beating estimates. Quarterly results were marked by broad-based profit growth across all operating segments. Pharmaceutical and Specialty Solutions benefited from robust brand and specialty drug sales, excluding the impact of a major contract expiration, while Global Medical Products and Distribution posted double-digit profit gains on higher volumes. The Other segment also saw significant expansion, supported by acquisitions and growth in at-Home Solutions, Nuclear and Precision Health Solutions, and logistics services.
Following positive results, shares of CAH were up 10% in pre-market trading. The company’s shares have gained 39.1% so far this year compared with the industry’s 4.1% increase. The S&P 500 Index has gained 18.6% in the period.
Image Source: Zacks Investment Research
Management’s ability to drive profitability while investing in strategic initiatives underscores the resilience and diversification of Cardinal Health’s business model. Ongoing progress in technology integration, supply-chain optimization, and specialty platform expansion further strengthen the company’s competitive positioning. With solid momentum across all five segments and a raised full-year outlook, Cardinal Health enters the remainder of fiscal 2026 with confidence.
CAH’s Zacks Rank and Stocks to Consider
Cardinal Health carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Solventum Corporation (SOLV - Free Report) , Boston Scientific Corporation (BSX - Free Report) and HealthEquity (HQY - Free Report) .
Solventum, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 4.1%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.91%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Solventum’s shares have gained 8.2% compared with the industry’s 6.2% growth so far this year.
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.1%.
Boston Scientific’s shares have gained 13.2% compared with the industry’s 5.6% growth so far this year.
HealthEquity, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.7%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 11.05%.
HealthEquity’s shares have risen 0.6% compared with the industry’s 6.2% growth so far this year.